Previous 10 | Next 10 |
Gainers: Natus Medical (NTUS) +30%. MedAvail (MDVL) +25%. IMARA (IMRA) +13%. Frequency Therapeutics (FREQ) +11%. Lyra Therapeutics (LYRA) +4%. Losers: Nektar Therapeutics (NKTR) -36%. TG Therapeutics (TGTX) -24%. Lixte Biotechnology (LIXT) -15%....
3 Penny Stocks to Add to Your Watchlist This Coming Week There’s a lot of debate surrounding penny stocks – are they worth investing in? Some people believe that penny stocks are a huge gamble, while others view them as a great way to make money. So, what’s the trut...
PASADENA, CA, April 14, 2022 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs for use in cancer treatment, today announced that it has closed a registered direct offering with certai...
WallachBeth Capital Announces Completion of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) $5.8 Million Registered Direct Offering PR Newswire JERSEY CITY, N.J. , April 14, 2022 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and...
Gainers: MedAvail Holdings (MDVL) +51%. Borqs Technologies (BRQS) +27%. Verastem (VSTM) +26%. Lexaria Bioscience (LEXX) +22%. Splash Beverage Group (SBEV) +18%. HighPeak Energy (HPK) +17%. Cardiol Therapeutics (CRDL) +16%. Airgain (AIRG) +15%. CoreCivic (CXW) +14%. Renren (RENN) +13%. Losers:...
Gainers: Lexaria Bioscience (LEXX) +23%. Rite Aid (RAD) +14%. Inozyme Pharma (INZY) +12%. Finch Therapeutics (FNCH) +11%. Valneva (VALN) +9%. Losers: Protagonist Therapeutics (PTGX) -23%. Lixte Biotechnology (LIXT) -10%. Biofrontera (BFRI) ...
NEW YORK, April 13, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEOs of: PolarityTE, Inc. (NASDAQ: PTE), Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), atai Life Sciences N....
WestPark Capital, Inc., a full-services investment bank and securities broker-dealer, today announced the completion of a Registered Direct Offering for Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage drug discovery company developing pharmacologically active drugs f...
WallachBeth Capital Announces Purchase and Sale of LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) PR Newswire $5.8 Million Registered Direct Offering Priced At-The-Market JERSEY CITY, N.J. , April 13 , 2022 /PRNewswire/ -- WallachBeth ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips After almost 12 months of underperformance, Lixte Biotechnology (NASDAQ: LIXT ) has skyrocketed by 200% in today’s trade. As an overview, Lixte is a clinical-stage biotechnology company. The massive rally in LI...
News, Short Squeeze, Breakout and More Instantly...
Lixte Biotechnology Holdings Inc. Company Name:
LIXT Stock Symbol:
OTCMKTS Market:
Lixte Biotechnology Holdings Inc. Website:
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ...
Clinical trial to test recent findings that show LIXTE’s lead clinical compound, LB-100, increases recognition of colon cancer cells by the immune system PASADENA, CA, June 14, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the ȁ...
LB-100 Generates Neo-Antigens in Cancer Cells that are Presented to the Immune System by Disrupting the Process of RNA Splicing PASADENA, CA, June 06, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) ( ...